Cutaneous Lupus Erythematosus Remission and Smoking
In patients with Cutaneous Lupus Erythematosus (CLE), long-term remission was rare and negatively related with smoking and discoid CLE.
In patients with Cutaneous Lupus Erythematosus (CLE), long-term remission was rare and negatively related with smoking and discoid CLE.
For patients with cutaneous lupus erythematosus (CLE), normal-appearing skin is a type I interferon-rich, prelesional environment.
A review of dermatological adverse events associated with anti-glaucoma eye drop is provided.
Current, evidence-based recommendations for the management of cutaneous lupus erythematosus (CLE) in the presence or absence of systemic lupus erythematosus (SLE) in adults, young people, and children are provided.
The efficacy of BIIBO59 in patients with cutaneous lupus erythematosus with and without concomitant systemic lupus erythematosus during 16 weeks was evaluated.
Patients with chronic inflammatory skin diseases (CISD) are at increased risk for significant morbidity from herpes zoster.
Investigators sought to determine whether patients with cutaneous lupus erythematosus have a similar frequency of antimalarial adverse cutaneous drug eruptions to patients with dermatomyositis.
Although patients with CCLE responded well, the numbers were small and additional research with respect to this finding is warranted.
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
A majority of the physician participants reported that CLASI was an easier tool to use compared with PGA.